Phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study): Phase Ib results

被引：0

作者：

Kagawa, Y. ^{[1
]}

Satake, H. ^{[2
]}

Kato, T. ^{[3
]}

Oba, K. ^{[4
]}

Yasui, H. ^{[5
]}

Nakamura, M. ^{[6
]}

Watanabe, T. ^{[7
]}

Hirata, K. ^{[8
]}

Muro, K. ^{[9
]}

Komatsu, Y. ^{[10
]}

Yoshino, T. ^{[11
]}

Yamazaki, K. ^{[12
]}

Mishima, H. ^{[13
]}

Kotaka, M. ^{[14
]}

Tsuji, A. ^{[15
]}

Kakeji, Y. ^{[16
]}

Oki, E. ^{[17
]}

Nagata, N. ^{[18
]}

Junichi, S. ^{[19
]}

机构：

[1] Kansai Rosai Hosp, Surg, Amagasaki, Hyogo, Japan

[2] Kansai Med Univ Hosp, Canc Treatment Ctr, Hirakata, Osaka, Japan

[3] Osaka Natl Hosp, Natl Hosp Org, Surg, Osaka, Japan

[4] Univ Tokyo, Dept Biostat, Tokyo, Japan

[5] Gen Hosp, Kobe City Med Ctr, Dept Med Oncol, Kobe, Hyogo, Japan

[6] Aizawa Hosp, Aizawa Comprehens Canc Ctr, Matsumoto, Nagano, Japan

[7] Himeji Hosp, Japanese Red Cross Soc, Dept Surg, Himeji, Hyogo, Japan

[8] Univ Occupat & Environm Hlth, Dept Surg, Kitakyushu, Japan

[9] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan

[10] Hokkaido Univ Hosp, Ctr Canc, Sapporo, Hokkaido, Japan

[11] Natl Canc Ctr Hosp, Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[12] Shizuoka Canc Ctr, Dept GI Oncol, Shizuoka, Japan

[13] Aichi Med Univ, Dept Surg, Nagakute, Aichi, Japan

[14] Sano Hosp, Gastrointestinal Canc Ctr, Surg, Kobe, Hyogo, Japan

[15] Kagawa Univ, Fac Med, Grad Sch Med, Dept Clin Oncol, Takamatsu, Kagawa, Japan

[16] Kobe Univ, Grad Sch Med, Dept Surg, Div Gastrointestibal Surg, Kobe, Hyogo, Japan

[17] Kyushu Univ Hosp, Dept Surg, Fukuoka, Fukuoka, Japan

[18] Kitakyushu Gen Hosp, Dept Surg, Kitakyushu, Fukuoka, Japan

[19] Tokai Cent Hosp, Kakamigahara, Japan

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

107P

引用

页数：2

共 50 条

[1] Multicenter phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study) - Trial in progress
Kato, T.
Satake, H.
Oba, K.
Kagawa, Y.
Yasui, H.
Nakamura, M.
Watanabe, T.
Matsumoto, T.
Hirata, K.
Muro, K.
Komatsu, Y.
Yoshino, T.
Yamazaki, K.
Mishima, H.
Kotaka, M.
Tsuji, A.
Kakeji, Y.
Oki, E.
Nagata, N.
Sakamoto, J.
ANNALS OF ONCOLOGY, 2018, 29 : 83 - 83
[2] Multicenter phase Ib/II study of biweekly trifluridine/tipiracil with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BITS study).
Kotaka, Masahito
Satake, Hironaga
Oba, Koji
Kagawa, Yoshinori
Yasui, Hisateru
Nakamura, Masato
Watanabe, Takanori
Matsumoto, Toshihiko
Kii, Takayuki
Terazawa, Tetsuji
Makiyama, Akitaka
Takano, Nao
Yokota, Mitsuru
Okita, Yoshihiro
Matoba, Koreatsu
Hasegawa, Hiroko
Tsuji, Akihito
Nagata, Naoki
Sakamoto, Junichi
Kato, Takeshi
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[3] A phase Ib study of irinotecan, bevacizumab and biweekly TAS-102 in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplation (MODURATE)
Taniguchi, H.
Narita, Y.
Kadowaki, S.
Ura, T.
Ando, M.
Muro, K.
Hamauchi, S.
Tsushima, T.
Yokota, T.
Todaka, A.
Machida, N.
Fukutomi, A.
Onozawa, Y.
Yasui, H.
Mori, K.
Yamazaki, K.
ANNALS OF ONCOLOGY, 2016, 27
[4] Final results of multicenter phase Ib/ II study of biweekly trifluridine/tipiracil with bevacizumab combination for patients with mCRC refractory to standard therapies (BiTS study)
Nakamura, Masato
Satake, Hironaga
Oba, Koji
Kotaka, Masahito
Kagawa, Yoshinori
Yasui, Hisateru
Watanabe, Takanori
Matsumoto, Toshihiko
Kii, Takayuki
Terazawa, Tetsuji
Makiyama, Akitaka
Takano, Nao
Yokota, Mitsuru
Okita, Yoshihiro
Matoba, Koreatsu
Hasegawa, Hiroko
Tsuji, Akihito
Nagata, Naoki
Sakamoto, Junichi
Kato, Takeshi
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[5] Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer
Ishizaki, Tetsuo
Mazaki, Junichi
Enomoto, Masanobu
Shigoka, Masatoshi
Kasahara, Kenta
Matsudo, Takaaki
Kawakita, Hideaki
Nagakawa, Yuichi
Katsumata, Kenji
Tsuchida, Akihiko
ANTICANCER RESEARCH, 2021, 41 (04) : 2157 - 2163
[6] Phase Ib/IIStudy of BiweeklyTAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTSStudy)
Satake, Hironaga
Kato, Takeshi
Oba, Koji
Kotaka, Masahito
Kagawa, Yoshinori
Yasui, Hisateru
Nakamura, Masato
Watanabe, Takanori
Matsumoto, Toshihiko
Kii, Takayuki
Terazawa, Tetsuji
Makiyama, Akitaka
Takano, Nao
Yokota, Mitsuru
Okita, Yoshihiro
Matoba, Koreatsu
Hasegawa, Hiroko
Tsuji, Akihito
Komatsu, Yoshito
Yoshino, Takayuki
Yamazaki, Kentaro
Mishima, Hideyuki
Oki, Eiji
Nagata, Naoki
Sakamoto, Junichi
ONCOLOGIST, 2020, 25 (12): : E1855 - E1863
[7] A multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE)
Yamazaki, K.
Kuboki, Y.
Nishina, T.
Shinozaki, E.
Shitara, K.
Okamoto, W.
Kajiwara, T.
Matsumoto, T.
Tsushima, T.
Mochizuki, N.
Fukutani, M.
Nakamoto, M.
Hasegawa, Y.
Sugama, A.
Nomura, S.
Sato, A.
Ohtsu, A.
Yoshino, T.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S368 - S369
[8] A multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE)
Nishina, T.
Kuboki, Y.
Shinozaki, E.
Yamazaki, K.
Kajiwara, T.
Shitara, K.
Matsumoto, T.
Tsushima, T.
Okamoto, W.
Mochizuki, N.
Nomura, S.
Sato, A.
Ohtsu, A.
Yoshino, T.
ANNALS OF ONCOLOGY, 2015, 26
[9] Phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO)
Boland, Patrick M.
Mukherjee, Sarbajit
Imanirad, Iman
Vijayvergia, Namrata
Cohen, Seth D.
Gupta, Medhavi
Iyer, Renuka V.
Chatley, Sarah
Cahill, Beth
Vadehra, Deepak
Attwood, Kristopher
Hochster, Howard S.
Fountzilas, Christos
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[10] Final survival results of a multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer patients refractory to standard therapies (C-TASK FORCE)
Yoshino, T.
Kuboki, Y.
Nishina, T.
Shinozaki, E.
Yamazaki, K.
Shitara, K.
Okamoto, W.
Kajiwara, T.
Matsumoto, T.
Tsushima, T.
Mochizuki, N.
Fukutani, M.
Nakamoto, M.
Hasegawa, H.
Sugama, A.
Nomura, S.
Sato, A.
Ohtsu, A.
ANNALS OF ONCOLOGY, 2016, 27 : 106 - 106

← 1 2 3 4 5 →